Skip to content

Clinical registry study of therapeutic embolization in the treatment of high grade cerebral arteriovenous malformations

Clinical registry study of therapeutic embolization in the treatment of high grade cerebral arteriovenous malformations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037562
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral arteriovenous malformation

Interventions

A:According to the situation, partial embolization is performed. Two large blood supply arterial microducts were selected in accordance with the two-catheter technique, and onyx was injected and the b
Onyx was injected into two microcatheters of large blood supply arteries according to double-catheter technique, and blood pressure was strictly controlled after operation
Intraoperative control hypotension was adopted.Blood pressure was strictly controlled after operation

Sponsors

The First Affiliated Hospital of PLA Navy Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
13 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. BAVM patients; 2. Agef 13 to 60 years; 3. The informed consent is signed by the patient himself or his legal guardian or representative.

Exclusion criteria

Exclusion criteria: 1. AVM has a history of embolization, radiation therapy or partial resection; 2. MRS >=3 points due to intracranial hemorrhage or neurological dysfunction before treatment; 3. Radiologically confirmed complicated with ruptured aneurysm; 4. AVM is too diffuse; 5. Platelet count 1.4, or TP or ATPP increased; 6. Any irreversible clotting disorder or known clotting disorder; 7. Patients requiring long-term anticoagulation;Premenopausal women with positive urine or plasma pregnancy tests (no recorded history of surgical sterilization); 8. Major concomitant diseases such as liver, kidney, gastrointestinal, respiratory, cardiovascular, endocrine, immune and hematological diseases that are subject to imaging safety assessment.

Design outcomes

Primary

MeasureTime frame
A. Immediate embolization rate after the last endovascular treatment and B. Vascular malformation occlusion rate following 2 years after the operation.;

Secondary

MeasureTime frame
A. Cerebral hemorrhage and ischemic events within one week after the last embolization; B. Cerebral hemorrhage events during clinical follow-up from 1 week after the last embolization to 2 years; C. MRS in the last clinical follow-up 2 years after the operation.;

Contacts

Public ContactQiang Li

The First Affiliated Hospital of PLA Navy Medical University

lqeimm@126.com+86 13818803656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026